JVC 001

Drug Profile

JVC 001

Alternative Names: JVC-001; Measles-mumps-and-rubella-virus-vaccine-Daiichi; MMR-vaccine-Daiichi-Sankyo; VN-0102

Latest Information Update: 17 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Japan Vaccine
  • Class Measles vaccines; Rubella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Measles; Mumps; Rubella

Most Recent Events

  • 01 Aug 2017 JVC 001 is still in phase I/II trials for Measles, Mumps and Rubella (Prevention) in Japan (Parenteral)
  • 31 Oct 2015 Phase-I/II clinical trials in Measles (Prevention) in Japan (Parenteral) (Daiichi Sankyo pipeline, October 2015)
  • 31 Oct 2015 Phase-I/II clinical trials in Mumps (Prevention) in Japan (Parenteral) (Daiichi Sankyo pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top